The 60/40 Rule: How Value-Based Procurement Changes What Surgical Technology Must Prove

For years, the conversation in NHS procurement ran like this: how much does it cost? What is the cheapest option that meets the minimum specification?

That changed on 11 June 2026.

NHS England formally rolled out Value-Based Procurement across all NHS trusts in England. Under the new framework, no more than 40% of any procurement score can be based on whole-life cost. At least 60% must be weighted on wider measures of value: patient outcomes, patient experience, and environmental impact.

After three years of development and pilots across 13 trusts, this is now the national standard. For surgical technology, it is a fundamental shift: not in whether evidence matters, but in what kind of evidence matters.

Under the previous model, the path to NHS adoption ran through procurement teams whose primary question was cost. A surgical robot, a simulation platform, an AI decision-support tool: all competed primarily on price per unit or cost per procedure.

Clinical evidence helped, but unless it translated to a clear cost saving within 12 months, it rarely moved the needle. Companies built their NHS commercial cases around cost efficiency. Outcome data, patient experience measures, and long-term value metrics were secondary. Evidence that a technology reduced complications by 30% was less compelling than evidence it saved a trust £50,000 in year one.

This is why devices with strong international evidence bases stalled in the NHS. The procurement system was not designed to recognise the kind of value they delivered.

Under VBP, the calculus flips. 60% of the procurement score depends on value metrics. For surgical technology, that means companies now need to demonstrate three things.

First, clinical outcome data relevant to NHS patient populations. Not just published trial data, but real-world evidence from NHS settings or comparable health systems, with documented translation to the local context.

Second, patient experience measures. Shorter recovery times. Improved quality-of-life metrics. Patient-reported outcomes. These now have formal weight in the scoring, which they never had before.

Third, system-level impact. Reduced readmissions. Shorter theatre times. Staff workload effects. The total value to the care pathway, not just the procedure. A robotic system that reduces complications and shortens recovery is expensive up front; the downstream saving often accrues to a different part of the NHS than the trust that paid for it.

Surgery is the area where the gap between technology capability and NHS adoption has been most visible. Robotic-assisted surgery, AI decision support, advanced simulation for training: all have evidence. Many have international adoption at scale. None have penetrated the NHS at the rate the evidence would suggest.

Part of the reason is that the procurement system was not built to recognise the value they deliver. VBP begins to fix that.

Audit your evidence. What outcome data do you have? Is it NHS-relevant? If not, what is the roadmap to generating it?

Understand the scoring framework. VBP gives trusts flexibility in how they weight the value criteria. Knowing what a specific trust prioritises, and mapping your evidence to those metrics, is now a core commercial capability.

Build clinical procurement champions. Under the old model, clinicians were often excluded from procurement conversations. VBP explicitly elevates outcomes evidence, which means the surgeon who can articulate what a technology does for patient experience is now a commercial asset, not just a clinical endorser.

The rules changed on 11 June. The companies that act on that first will have a structural advantage that compounds.